Synthorx, Inc.
Synthorx, Inc., a pioneering biotechnology company based in the United States, focuses on the development of innovative therapeutics through its proprietary synthetic biology platform. Founded in 2014, Synthorx has made significant strides in the biopharmaceutical industry, particularly in the areas of immuno-oncology and protein therapeutics.
The company is renowned for its unique approach to expanding the genetic code, enabling the creation of novel proteins with enhanced therapeutic properties. Synthorx's lead product candidate, THOR-707, exemplifies this innovation, targeting cancer treatment with a differentiated mechanism of action.
With a strong market position, Synthorx has garnered attention for its groundbreaking research and development efforts, positioning itself as a leader in the synthetic biology space. The company continues to advance its mission of transforming patient care through cutting-edge science and technology.
+62 vs industry average
Synthorx, Inc.’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Synthorx, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Synthorx, Inc. yet.
Synthorx, Inc.'s reported carbon emissions
Synthorx, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Sanofi, and any climate commitments or emissions data may be inherited from its parent organisation.
As part of its corporate family relationship with Sanofi, Synthorx aligns with various climate initiatives, including the Science Based Targets initiative (SBTi), CDP, and RE100, all of which are cascaded from Sanofi. However, specific reduction targets or achievements for Synthorx are not detailed in the available information.
While no direct emissions data or reduction targets are provided for Synthorx, the company's affiliation with Sanofi suggests a commitment to sustainability and climate action, reflecting industry standards for reducing carbon footprints. Further details on Synthorx's specific climate commitments may be available through Sanofi's broader sustainability reporting.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Synthorx, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Synthorx, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from Sanofi
Carbon Disclosure Project
Inherited from SanofiThe Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from SanofiRE 100
Inherited from SanofiClimate Action 100
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for Synthorx, Inc. yet.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project